Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"<b><i>NUCKS1</i></b> Acts as a Promising Novel Biomarker for the Prognosis of Patients with Hepatocellular Carcinoma.","authors":"Xianfeng Zhang, Xianjun Zhang, Xinguo Li, Hongbing Bao, Guang Li, Ning Li, Hengli Li, Jian Dou","doi":"10.1089/cbr.2020.4226","DOIUrl":"10.1089/cbr.2020.4226","url":null,"abstract":"<p><p><b><i>Objective:</i></b> Nuclear casein kinase and cyclin-dependent kinase substrate 1 (<i>NUCKS1</i>) is highly expressed in some tumors, including hepatocellular carcinoma (HCC). However, its clinical significance in HCC prognosis is still unclear. The aim of this study was to explore the expression and prognostic value of <i>NUCKS1</i> in HCC. <b><i>Materials and Methods:</i></b> Quantitative real-time polymerase chain reaction was used to detect relative expression of <i>NUCKS1</i> mRNA in HCC tissues and corresponding adjacent normal tissues. The relationship between <i>NUCKS1</i> expression and clinical characteristics of patients was analyzed by χ² test. Kaplan-Meier method and Cox regression analysis were applied to estimate prognostic value of <i>NUCKS1</i> in HCC. <b><i>Results:</i></b> Compared with normal ones, the expression of <i>NUCKS1</i> mRNA was significantly upregulated in HCC tissues (<i>p</i> < 0.001). Besides, <i>NUCKS1</i> expression was closely associated with tumor differentiation, tumor node metastasis stage, vascular invasion, and metastasis (<i>p</i> < 0.05). Kaplan-Meier analysis revealed that overall survival was obviously longer in HCC patients with low expression of <i>NUCKS1</i> than those with high <i>NUCKS1</i> expression (log rank test, <i>p</i> = 0.001). <i>NUCKS1</i> might be an independent prognostic factor for HCC patients (HR = 1.905, 95% CI = 1.106-3.283, <i>p</i> = 0.020). <b><i>Conclusions:</i></b> <i>NUCKS1</i> may be correlated with the progression of HCC and serve as a potential predictive factor for the prognosis of this disease.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25381343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circ_0058058 Knockdown Inhibits Acute Myeloid Leukemia Progression by Sponging miR-4319 to Regulate <i>EIF5A2</i> Expression.","authors":"Ting Zhang, Ying Zhou, Jun Guan, Hui Cheng","doi":"10.1089/cbr.2020.4170","DOIUrl":"10.1089/cbr.2020.4170","url":null,"abstract":"<p><p><b><i>Background:</i></b> Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Circular RNAs (circRNAs) participate in the deterioration of many hominine cancers, including AML. In this study, the authors investigated the role and potential mechanism of circ_0058058 in AML progression. <b><i>Methods:</i></b> The expression of circ_0058058, microRNA-4319 (miR-4319), and eukaryotic initiation factor 5A2 (<i>EIF5A2</i>) was determined by quantitative real-time polymerase chain reaction. Cell proliferation, apoptosis, migration, and invasion were evaluated by cell counting kit-8 (CCK-8), cell colony formation, flow cytometry, and transwell assay, respectively. Levels of the relative proteins were detected by Western blot. The connection among circ_0058058, miR-4319, and <i>EIF5A2</i> was verified by dual-luciferase reporter assay. <b><i>Results:</i></b> Circ_0058058 and <i>EIF5A2</i> were enhanced, whereas miR-4319 was declined in AML. Circ_0058058 knockdown inhibited cell proliferation, migration, and invasion, and facilitated cell apoptosis by targeting miR-4319 in AML cells. Moreover, as a target of miR-4319, <i>EIF5A2</i> overexpression overturned the inhibitory effects of miR-4319 upregulation on AML progression. Besides, circ_0058058 sponged miR-4319 to upregulate <i>EIF5A2</i> expression in AML cells. <b><i>Conclusion:</i></b> Circ_0058058 knockdown inhibited cell proliferation, migration, and invasion, but accelerated cell apoptosis by reducing <i>EIF5A2</i> expression by targeting miR-4319, suggesting that circ_0058058 could be a therapeutic target for the treatment of AML.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38839194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of ^99mTc-Sestamibi Heart/Liver Uptake Ratio in Screening Nonalcoholic Fatty Liver Disease During Myocardial Perfusion Imaging.","authors":"Ghazal Norouzi, Sara Nikdel, Elahe Pirayesh, Yazdan Salimi, Mahasti Amoui, Hamidreza Haghighatkhah, Mohammad Ali Ghodsi Rad, Elmira Javanijouni, Sepideh Khoshbakht","doi":"10.1089/cbr.2022.0062","DOIUrl":"10.1089/cbr.2022.0062","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> Nonalcoholic fatty liver disease (NAFLD) is the most common chronic hepatic disease worldwide, with functional impairment of the mitochondria occurring from early stages. Technetium-99m methoxy-isobutyl-isonitrile (^99mTc-MIBI) is a lipophilic agent trapped in the mitochondria. This study aims to evaluate the utility of ^99mTc-MIBI heart/liver uptake ratio in screening for NAFLD during myocardial perfusion imaging (MPI). <b><i>Methods:</i></b> Seventy eligible patients underwent a 2-d rest/stress ^99mTc-MIBI scan with a 2-min planar image acquired in rest phase, at 30, 60, and 120 min postradiotracer administration. Heart/liver uptake ratio was calculated by placing identical regions of interest on the heart and liver dome. All patients underwent liver ultrasound and were allocated into groups A, having NAFLD; and B, healthy individuals without NAFLD. <b><i>Results:</i></b> Mean count per pixel heart/liver ratios gradually increased over time in either group; nonetheless the values were significantly higher in group A, regardless of acquisition timing; with the <i>p</i>-value equal to 0.007, 0.014, and 0.010 at 30, 60, and 120 min, respectively. <b><i>Conclusion:</i></b> Determining ^99mTc-MIBI heart/liver uptake ratio during rest phase in patients undergoing MPI may be a useful, noninvasive screening method for NAFLD; with no additional cost, radiation burden, or adverse effects in these patients. Trial registration number: IR.SBMU.MSP.REC.1398.308.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10448509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues.","authors":"Wang-Yang Ye, Hui-Ping Lu, Jian-Di Li, Gang Chen, Rong-Quan He, Hua-Yu Wu, Xian-Guo Zhou, Min-Hua Rong, Li-Hua Yang, Wei-Ying He, Qiu-Yu Pang, Shang-Ling Pan, Yu-Yan Pang, Yi-Wu Dang","doi":"10.1089/cbr.2020.4342","DOIUrl":"10.1089/cbr.2020.4342","url":null,"abstract":"<p><p><b><i>Background:</i></b> To date, the clinical management of advanced hepatocellular carcinoma (HCC) patients remains challenging and the mechanisms of E2F transcription factor 1 (E2F1) underlying HCC are obscure. <b><i>Materials and Methods:</i></b> Our study integrated datasets mined from several public databases to comprehensively understand the deregulated expression status of E2F1. Tissue microarrays and immunohistochemistry staining was used to validate E2F1 expression level. The prognostic value of E2F1 was assessed. In-depth subgroup analyses were implemented to compare the differentially expressed levels of E2F1 in HCC patients with various tumor stages. Functional enrichments were used to address the predominant targets of E2F1 and shedding light on their potential roles in HCC. <b><i>Results:</i></b> We confirmed the elevated expression of E2F1 in HCC. Subgroup analyses indicated that elevated E2F1 level was independent of various stages in HCC. E2F1 possessed moderate discriminatory capability in differentiating HCC patients from non-HCC controls. Elevated E2F1 correlated with Asian race, tumor classification, neoplasm histologic grade, eastern cancer oncology group, and plasma AFP levels. Furthermore, high E2F1 correlated with poor survival condition and pooled HR signified E2F1 as a risk factor for HCC. Enrichment analysis of differentially expressed genes, coexpressed genes, and putative targets of E2F1 emphasized the importance of cell cycle pathway, where <i>CCNE1</i> and <i>CCNA2</i> served as hub genes. <b><i>Conclusions:</i></b> We confirmed the upregulation of E2F1 and explored the prognostic value of E2F1 in HCC patients. Two putative targeted genes (<i>CCNE1</i> and <i>CCNA2</i>) of E2F1 were identified for their potential roles in regulating cell cycle and promote antiapoptotic activity in HCC patients.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39493984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening and Preclinical Evaluation of Novel Radiolabeled Anti-Fibroblast Activation Protein-α Recombinant Antibodies.","authors":"Jianfeng Xu, Shenghua Li, Shasha Xu, Juan Dai, Zhigang Luo, Jingjing Cui, Fei Cai, Changran Geng, Zheng Wang, Xiaobin Tang","doi":"10.1089/cbr.2021.0389","DOIUrl":"10.1089/cbr.2021.0389","url":null,"abstract":"<p><p><b><i>Background:</i></b> Fibroblast activation protein-α (FAPα) is selectively overexpressed in tumor-associated fibroblasts in more than 90% of epithelial tumors, and may be a good target for anticancer treatment, for example, using an anti-FAPα recombinant antibody (rAb) labeled with radionuclides. In the present report, the radiolabeling and preclinical evaluation of novel anti-FAPα rAbs were investigated. <b><i>Materials and Methods:</i></b> Two novel anti-FAPα VHHs (AMS002-1 and AMS002-2) with high binding affinity to FAPα were selected from an antibody phage library. The anti-FAPα VHHs were then fused with the Fc fragment of human IgG4 to create two VHH-Fc rAbs. The VHH-Fc rAbs were radiolabeled with ⁸⁹Zr and ¹⁷⁷Lu. The radiolabeled products were evaluated by radioligand-binding assays using FAPα-expressing cells. The biodistribution and tumor-targeting properties were investigated by small-animal PET/CT. AMS002-1-Fc, which showed promising tumor-targeting properties in ⁸⁹Zr-microPET imaging, was radiolabeled with ¹⁷⁷Lu for efficacy study on HT1080 tumor-bearing mice and monitored with SPECT/CT imaging. <b><i>Results:</i></b> The two VHH-Fc rAbs with good affinity with K_D values in low nanomolar range were identified. Both PET/CT imaging with ⁸⁹Zr-AMS002-1-Fc rAb and SPECT/CT imaging with ¹⁷⁷Lu-AMS002-1-Fc rAb demonstrated highest tumor uptakes at 72 h p.i. and long tumor retention in the preclinical models. Furthermore, <i>ex vivo</i> biodistribution analysis revealed high tumor uptake of ⁸⁹Zr-AMS002-1-Fc at 48 h p.i. with the value of 6.91% ± 2.08% ID/g. Finally, radioimmunotherapy with ¹⁷⁷Lu-AMS002-1-Fc rAb delayed the tumor growth without significant weight loss in mice with HT1080 xenografts. The tumor size of untreated control group was 2.59 times larger compared with the treatment group with ¹⁷⁷Lu-AMS002-1-Fc at day 29. <b><i>Conclusion:</i></b> ⁸⁹Zr/¹⁷⁷Lu-AMS002-1-Fc represent a pair of promising radiopharmaceuticals for theranostics on FAPα-expressing tumors.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90659594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-424 Acts as a Novel Biomarker in the Diagnosis of Patients with Hepatocellular Carcinoma.","authors":"Chao Yang, Peng Du, Wei Lu","doi":"10.1089/cbr.2020.4141","DOIUrl":"10.1089/cbr.2020.4141","url":null,"abstract":"<p><p><b><i>Objective:</i></b> MicroRNA-424 (MiR-424) is proved to be a tumor suppressor against many malignancies, including hepatocellular carcinoma (HCC). Nevertheless, its role in diagnosing HCC remained poorly understood. The authors' research investigated diagnostic value of serum miR-424 in HCC. <b><i>Materials and Methods:</i></b> Relative expression levels of serum miR-424 in HCC patients and healthy individuals were measured via quantitative real-time polymerase chain reaction. χ² test was applied to analyze the correlation between miR-424 expression and clinical features of HCC cases. Diagnostic value was estimated via plotting a receiver operating characteristic (ROC) curve. <b><i>Results:</i></b> Serum miR-424 expression was obviously downregulated in HCC cases in comparison to healthy persons (<i>p</i> < 0.001). miR-424 expression presented strong correlation with tumor node metastasis stage (<i>p</i> = 0.022), Barcelona Clinic Liver Cancer stage (<i>p</i> < 0.001), metastasis (<i>p</i> = 0.037), and vein invasion (<i>p</i> = 0.033). ROC curve analysis manifested an area under the curve of 0.768 with a sensitivity of 75.0% and a specificity of 72.4%, suggesting that serum miR-424 had high diagnostic value in HCC patients. <b><i>Conclusions:</i></b> The data suggest that serum miR-424 may represent a biomarker in early detection of HCC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39205466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosomal circFBLIM1 Promotes Hepatocellular Carcinoma Progression and Glycolysis by Regulating the miR-338/LRP6 Axis.","authors":"Zhiwen Lai, Tianning Wei, Qingming Li, Xianglong Wang, Yang Zhang, Shengliang Zhang","doi":"10.1089/cbr.2020.3564","DOIUrl":"10.1089/cbr.2020.3564","url":null,"abstract":"<p><p><b><i>Background:</i></b> Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Circular RNAs (circRNAs) play a vital role in cancer development and progression. This study investigated the role and potential mechanism of circRNA filamin binding LIM protein 1 (circFBLIM1) in HCC. <b><i>Methods:</i></b> Exosomes were identified by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot assay. The levels of circFBLIM1, miR-338, and low-density lipoprotein receptor-related protein 6 (LRP6) were measured by quantitative real-time polymerase chain reaction or Western blot. Glycolysis was analyzed by detecting glucose consumption, lactate production, ATP level, extracellular acidification rate (ECAR), and oxygen consumption rate (OCR). Cell viability was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Cell apoptosis was detected by flow cytometry. Xenograft assay was performed to analyze tumor growth <i>in vivo</i>. The interaction among circFBLIM1, miR-338, and LRP6 was confirmed by dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine. <b><i>Results:</i></b> CircFBLIM1 was highly expressed in HCC serum exosomes and HCC cells. Inhibition of circFBLIM1 confined HCC glycolysis and progression. CircFBLIM1 knockdown blocked tumorigenesis <i>in vivo</i>. CircFBLIM1 was a sponge of miR-338 and promoted HCC progression and glycolysis by regulating miR-338. Moreover, miR-338 suppressed HCC progression and glycolysis via targeting LRP6. Mechanistically, circFBLIM1 functioned as an miR-338 sponge to upregulate LRP6. <b><i>Conclusion:</i></b> CircFBLIM1 facilitated HCC progression and glycolysis via modulating the miR-338/LRP6 axis, which may provide promising therapeutic targets for HCC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.2020.3564","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38362734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circ_0004913 Inhibits Cell Growth, Metastasis, and Glycolysis by Absorbing miR-184 to Regulate <i>HAMP</i> in Hepatocellular Carcinoma.","authors":"Mingyuan Wu, Tanlezi Sun, Lianjun Xing","doi":"10.1089/cbr.2020.3779","DOIUrl":"10.1089/cbr.2020.3779","url":null,"abstract":"<p><p><b><i>Background:</i></b> Circular RNA (circRNA) can regulate the progression of hepatocellular carcinoma (HCC). However, the role and potential mechanism of circ_0004913 in HCC are not explored. <b><i>Methods:</i></b> Circ_0004913 was identified from two GSE datasets (GSE94508 and GSE97322) as a differentially expressed circRNA between HCC and normal tissues. Levels of circ_0004913, microRNA-184 (miR-184), and hepcidin (<i>HAMP</i>) were determined by quantitative real-time polymerase chain reaction (qRT-PCR). Cell proliferation, migration, and invasion were estimated by methyl thiazolyl tetrazolium, colony formation, and Transwell assays, respectively. Levels of all proteins were examined by Western blot. Glucose consumption and lactate and ATP production were analyzed by the glucose, lactate, and ATP assay kits. Dual-luciferase reporter, RNA immunoprecipitation (RIP), and RNA pull-down assays were performed to verify the interactions among miR-184 and circ_0004913 or <i>HAMP</i>. The mice xenograft models were established to assess the effect of circ_0004913 on tumor growth <i>in vivo</i>. <b><i>Results:</i></b> Circ_0004913 was downregulated in HCC, and its expression impeded cell proliferation, migration, and invasion, EMT, and glycolysis in HCC cells. miR-184 was identified as a target miRNA of circ_0004913, and their expression levels were negatively correlated. miR-184 overexpression could reverse the inhibitory effect of circ_0004913 on HCC cell progression. Moreover, as a target gene of miR-184, <i>HAMP</i> expression was positively correlated with circ_0004913 expression in HCC tissues, and repression of miR-184 could inhibit the progression of HCC cells by increasing <i>HAMP</i> expression. Circ_0004913 could inhibit JAK2/STAT3/AKT signaling pathway and tumor growth <i>in vivo</i> by regulating the miR-184/<i>HAMP</i> axis. <b><i>Conclusion:</i></b> Circ_0004913 inhibited the tumorigenesis of HCC by sponging miR-184 to regulate <i>HAMP</i> expression <i>in vitro</i> and <i>in vivo</i>.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.2020.3779","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38458262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triangle of Trust in Cancer Care? The Physician, the Patient, and Artificial Intelligence Chatbot.","authors":"J Harvey Turner","doi":"10.1089/cbr.2023.0112","DOIUrl":"10.1089/cbr.2023.0112","url":null,"abstract":"<p><p>Trust, as a philosophic paradigm, is predominantly interpersonal, between human beings, and is differentiated from reliance. Can a person trust an inhumane amoral agent, such as a large language model artificial intelligence (AI) chatbot, to manifest the goodwill and willingness normally required in order for it to be deemed trustworthy? This article explores the relationship between the cancer patient, their physician, and AI chatbot in a proposed tripartite, consultative, personalized approach to shared-care in precision molecular oncology. It examines the nature of trust between human agents and machines. It also contemplates AI-enhanced technical precision in state-of-the-art cancer management, complemented by trustworthy, holistic clinical care by a physician, for each individual patient. \"<i>To what extent can the user</i> \"<i>trust</i>\" <i>GPT-4?</i>\" Peter Lee,¹ Microsoft Research 2023.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10245036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Long Noncoding RNA ZEB2-AS1 Contributes to Proliferation and Epithelial-to-Mesenchymal Transition of Osteosarcoma.","authors":"Jiexiang Yang, Yonggen Zou, Jian Wu, Bo Chen, Cheng Luo, Xiaojun Chen, Huarui Shen, Lin Luo","doi":"10.1089/cbr.2019.3433","DOIUrl":"10.1089/cbr.2019.3433","url":null,"abstract":"<p><p><b><i>Background:</i></b> Long non-coding RNA Zinc finger E-box binding homeobox 2 (ZEB2) antisense RNA 1 (ZEB2-AS1) has been shown to promote tumor progression. However, the clinical significance and fundamental function role of ZEB2-AS1 in osteosarcoma (OS) has been poorly understood. <b><i>Methods:</i></b> The expression of ZEB2-AS1 was determined in tumor tissues and matched normal tissues from 67 OS patients using quantitative reverse transcriptase PCR analysis. Clinical value of ZEB2-AS1 was evaluated by χ² test and Kaplan-Meier method. Cell proliferation was analyzed using CCK-8 assay, colony formation. Cell apoptosis status was determined by caspase-3 activity assay. Cell migration, invasion and epithelial-mesenchymal transition (EMT) were investigated by scratch wound healing, transwell invasion assays and Western blotting. <b><i>Results:</i></b> Clinical association analysis revealed that high ZEB2-AS1 expression correlated with tumor size, distant metastasis and poor prognosis of OS patients. Moreover, ZEB2-AS1 expression was identified as an independent prognostic factor for OS patients. Loss-of-function assays demonstrated that ZEB2-AS1 knockdown suppressed the proliferation and induced apoptosis in OS cells. In addition, ZEB2-AS1 knockdown inhibited cell migration, invasion, EMT of OS cells <i>in vitro</i>. <b><i>Conclusions:</i></b> Taken together, our data demonstrate that ZEB2-AS1 serves a putative oncogenic role and associates with unfavorable prognosis in OS.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.2019.3433","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38519490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}